Category: Side Effect: Kidney Injury (chronic kidney disease, acute renal failure)
-
Heart Failure Drug Natrecor Fails Efficacy Part Of “Off-label” Use Study
Safety Profile Of Natrecor Continues To Be Subject Of Controversy And Debate (Posted by Tom Lamb at DrugInjuryWatch.com) The results of a large study for Johnson & Johnson’s heart failure drug Natrecor failed to…
-
Natrecor: Is Controversial J&J Heart Failure Drug Harmful Or Harmless?
Scios Announces Study To Address Safety Issues But Results Not Expected For Several Years In the October 1, 2006 issue of the medical journal Pharmacotherapy is an article which emphasizes the need to resolve…
-
Natrecor: A Definitive Safety Study Is Long Overdue
Off-label Use Of Natrecor Continues To Be A Problem A year ago two medical journal articles raised serious safety issues about Natrecor; in summary: (1) a 50% increased risk of kidney damage or renal…
-
Zocor-Amiodarone Drug Interaction Causes Rhabdomyolysis; Fifth Such Case Reported
Causation Theory: Zocor Is Metabolized By Same Enzyme Which Is Being Inhibited By Amiodarone On March 14, 2006 The Annals of Pharmacotherapy published online an article about what the authors described as "the fifth…
-
FDA Reviewing Safety Of Bayer’s Heart Surgery Drug Trasylol
Studies Link Trasylol To Kidney Problems, Heart Attacks, and Strokes In mid-February 2006 the FDA issued a Public Health Advisory informing doctors and patients that the agency was evaluating the safety of Bayer AG’s…
-
Scios Says Two Deaths In Natrecor Trial Were Not Reported To FDA
Latest Natrecor News Increases Safety Concerns About J&J Heart Failure Drug The Scios unit of Johnson & Johnson (J&J) did not immediately report to the FDA two deaths from a clinical trial, or study,…
-
Controversy Over Safety of Heart Failure Drug Natrecor Continues
Doubting Its Safety, Dr. Eric Topol and Others Want Natrecor Recalled In the October 6, 2005 issue of The New England Journal of Medicine ("NEJM") appears a letter to the editor by Jonathan Sackner-Bernstein,…
-
Scios Sends Second “Dear Doctor” Letter On Heart Drug Natrecor
Cardiologist Eric Topol Calls For Limited Use of Johnson & Johnson Drug Natrecor On July 13, 2005 the Scios division of Johnson & Johnson sent a second "Dear Doctor" letter about Natrecor, a heart-failure…
-
Drug-induced Rhabdomyolysis and Acute Renal Failure (ARF) Cases On Increase
Rhabdomyolysis is Result of Skeletal Muscle Injury Caused by Drugs (and Other Things) The number of drug-induced rhabdomyolysis adverse event reports submitted to the FDA is rising, seemingly due to the introduction to market…
-
Crestor Side Effects: Reports to FDA MedWatch Analyzed by Tufts Doctors
Crestor-Rhabdomyolysis Link: New Study May Support Allegations by Public Citizen Group Rhabdomyolysis, proteinuria, nephropathy, and kidney or renal failure are serious side effects which apparently occur more often with the use of Crestor (rosuvastatin)…